Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsWith over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications. Highlights
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsCHO stable expression system is an ideal choice for recombinant proteins produced in large scale. As a totipotent services provider, Creative Biolabs develops various CHO stable cell lines and reengineered CHO cell lines for biotherapeutic proteins characterization, developability assessment, and manufacturing uses.
With the rapid development of protein biopharmaceuticals, especially these therapeutic recombinant monoclonal antibodies, a stable protein expression system is of great significance for biotechnological manufacture. Different from the transient gene expression system, target DNAs of stable cell lines expression system are usually integrated into the chromosomes of host cells, which can be expressed and passed on with cell proliferation. Stable mammalian cell lines are preferred for protein production with unique advantages. Currently, the most extensively and frequently used mammalian cells in research or industrial are human embryonic kidney 293 cells (HEK-293) and Chinese Hamster Ovary (CHO) cell lines. Biologics expressed in CHO cells approved in the United States and Europe accounted for about 80% of currently approved therapeutic proteins.
One of the remarkable advantages of utilizing CHO cell lines for therapeutic protein production is the similarity to the human cell system, which means lower immunogenicity and better compatibility for human disease therapy. Additionally, CHO stable cell lines offer high-yield and high-quality protein production in persistent and stable manners. Deficiently, protein expression in CHO stable cell lines is relatively time-/cost-consuming due to resistance selection and amplification, but these limitations have been improved by novel biotechnologies recently.
Fig.1 Illustration of a typical process to develop a mammalian cell line for recombinant protein manufacturing. (Lai, 2013)
To develop a commercial biotherapeutic protein, two critical aspects of the candidates should be firstly considered that are expression titer and purification yield. CHO stable cell lines are preferred for the productivity assessment since they provide gram quantities of protein production with consistent quality.
Furthermore, besides CHO productivity assessment, manufacturability assessment also involves many other experimental evaluations, including physical stability assessment, chemical stability tests and post-translational modification assessment, and pre-formulation research, all of which require a large number of high-purity proteins. CHO stable cell line is the preferred expression system which can provide a large number of stable protein candidates source for various detailed characterizations and manufacturability assessments.
Taking full use of the advantages of our advanced CreDA™ platform, Creative Biolabs offers CHO productivity assessment services as well as other related manufacturability assessment services to help our global customers select biopharmaceuticals with high productivity for further process development. To discuss your therapeutic protein developability assessment demands or to request a proposal, please free to contact us for more detailed information.
Reference
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
